06.11.2019 | ASO Author Reflections
ASO Author Reflections: High Stromal TGFBI is a Useful Predictive Marker for Nivolumab in Non-small Cell Lung Cancer
verfasst von:
Nobuhiro Nakazawa, MD, Takehiko Yokobori, MD, PhD, Andrei Turtoi, MD, PhD, Ken Shirabe, MD, PhD, FACS
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 3/2020
Einloggen, um Zugang zu erhalten
Excerpt
Recently, the anti-PD-1 antibody nivolumab has been found to be promising to improve survival of non-small cell lung cancer (NSCLC) patients. It was reported that NSCLC patients treated with nivolumab showed good therapeutic responses and improved survival intervals via activation of cytotoxic T lymphocytes (CTL).
1,2 However, more effective identification of good responders among NSCLC patients treated with nivolumab requires the development of novel sensitive and specific biomarkers that can be evaluated cost-efficiently by routine means. Mariathasan et al.
3 suggested that evaluation of TGF-β signaling might be a good candidate as a nivolumab sensitivity marker. However, a suitable method for evaluating TGF-β signaling in cancer patients treated with immune checkpoint inhibitors is lacking. We focused on the transforming growth factor-beta-induced protein (TGFBI), one of the representative downstream genes of TGF-β signaling.
4 The purpose of this study is to clarify the significance of TGFBI and immune cells in clinical lung cancer patients treated with nivolumab. …
